Javascript must be enabled to continue!
CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy
View through CrossRef
Introduction
CD137 (4-1BB), a member of the tumour necrosis factor (TNF) receptor superfamily, plays a key role in T-cell activation, survival, and cytokine production, functions that are central to immune responses against
Mycobacterium tuberculosis
. This scoping review brings together current evidence on the clinical relevance of CD137 in tuberculosis (TB), including its potential as a diagnostic, prognostic, and therapeutic target.
Methods
This review was conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR). Relevant studies on CD137 in TB were identified through database searches and screened using predefined eligibility criteria. Experimental, animal, and human studies reporting on CD137 expression, function, or clinical associations were included. Key information from each study was charted to describe the scope, characteristics, and main findings of the available evidence.
Results
We identified ten eligible studies involving
in vitro
experiments, animal models, and human cohorts. CD137-positive T cells and soluble CD137 (sCD137) levels were consistently elevated in active TB, with some evidence suggesting the ability to distinguish disease states and predict severity. Mechanistic studies show that CD137 modulates cytokine responses, including interferon-gamma (IFN-γ) and TNF-α, and interacts with other immune checkpoints such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). Preclinical models have demonstrated that CD137-targeted strategies may enhance mycobacterial control. Although current findings are promising, most studies are small, geographically limited, and exploratory.
Discussion
CD137 remains an underexplored immune checkpoint with potential to inform host-directed TB diagnostics and therapies, offering a new angle for precision immunology in high-burden settings. Large-scale, longitudinal studies are needed to define its role in host immunity and determine its translational value.
Frontiers Media SA
Title: CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy
Description:
Introduction
CD137 (4-1BB), a member of the tumour necrosis factor (TNF) receptor superfamily, plays a key role in T-cell activation, survival, and cytokine production, functions that are central to immune responses against
Mycobacterium tuberculosis
.
This scoping review brings together current evidence on the clinical relevance of CD137 in tuberculosis (TB), including its potential as a diagnostic, prognostic, and therapeutic target.
Methods
This review was conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR).
Relevant studies on CD137 in TB were identified through database searches and screened using predefined eligibility criteria.
Experimental, animal, and human studies reporting on CD137 expression, function, or clinical associations were included.
Key information from each study was charted to describe the scope, characteristics, and main findings of the available evidence.
Results
We identified ten eligible studies involving
in vitro
experiments, animal models, and human cohorts.
CD137-positive T cells and soluble CD137 (sCD137) levels were consistently elevated in active TB, with some evidence suggesting the ability to distinguish disease states and predict severity.
Mechanistic studies show that CD137 modulates cytokine responses, including interferon-gamma (IFN-γ) and TNF-α, and interacts with other immune checkpoints such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).
Preclinical models have demonstrated that CD137-targeted strategies may enhance mycobacterial control.
Although current findings are promising, most studies are small, geographically limited, and exploratory.
Discussion
CD137 remains an underexplored immune checkpoint with potential to inform host-directed TB diagnostics and therapies, offering a new angle for precision immunology in high-burden settings.
Large-scale, longitudinal studies are needed to define its role in host immunity and determine its translational value.
Related Results
The role of soluble CD137 in development of liver cirrhosis among hepatitis B virus infected individuals
The role of soluble CD137 in development of liver cirrhosis among hepatitis B virus infected individuals
Introduction: Viral and tumor management are mediated by the production of CD137 as a co-receptor for T cells. Objective: The purpose of the research is to examine the link between...
CD137-CD137L Signaling Affects Angiogenesis by Mediating Phenotypic Conversion of Macrophages
CD137-CD137L Signaling Affects Angiogenesis by Mediating Phenotypic Conversion of Macrophages
Background:
Angiogenesis in atherosclerotic plaque is an important factor causing plaque hemorrhage, vulnerability, and rupture, and different phenotypes of macrophages...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling
CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling
Abstract
Background: CD137 is a target for tumor immunotherapy. However, the role of CD137 in gastric cancer (GC), especially in inducing GC cell apoptosis, has not been st...
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
<p dir="ltr">Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis), remains a leading global health concern, responsible for millions of inf...
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
<p dir="ltr">Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis), remains a leading global health concern, responsible for millions of inf...
Multiplex Immunofluorescence reveals specific subsets of immune cell populations expressing CD137/TNFRSF9 as predictors of unfavorable outcomes in Hodgkin Lymphoma
Multiplex Immunofluorescence reveals specific subsets of immune cell populations expressing CD137/TNFRSF9 as predictors of unfavorable outcomes in Hodgkin Lymphoma
The tumor microenvironment (TME) is a crucial determinant of tumor growth, progression, and resistance to chemotherapy in cancer, with classical Hodgkin's lymphoma (cHL) being one ...

